|
|
Basic and Clinical Neuroscience، جلد ۱۶، شماره ۵، صفحات ۰-۰
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Subthalamic Nucleus Deep Brain Stimulation in Early-Onset Parkinson's Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers |
|
| چکیده انگلیسی مقاله |
Introduction: Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) is an established treatment for early-onset Parkinson’s disease (EOPD). While the effect of STN-DBS on patients with LRRK2-G2019S mutation has been largely investigated, data specific to EOPD patients with this mutation remain scarce. This study assesses how the G2019S mutation impacts STN-DBS outcomes in EOPD patients in Morocco, a developing country where such treatment is challenging to provide.
Methods: A prospective cohort study was conducted at the University Hospital of Ibn Rochd in Casablanca. Genomic DNA was analyzed for LRRK2-G2019S mutation, and clinical data were collected pre- and post-surgery. Motor outcomes, including dyskinesia, motor fluctuations, and levodopa equivalent daily dose (LEDD) reduction, were assessed one-year post-DBS.
Results: Seventeen EOPD patients who underwent STN-DBS were included, with 10 (58.8%) being LRRK2-G2019S mutation carriers. The mean age of participants was 57.2 ± 8.4 years, with an average age at onset of 37.9 ± 6.2 years. Motor fluctuations were present in 88.2% of patients, and 94.1% experienced dyskinesia. Post-DBS, both mutation carriers and non-carriers showed significant improvements in motor symptoms, with a mean UPDRS III improvement of 61.3%. Dyskinesia and motor fluctuations, as measured by specific UPDRS IV items, improved by 77.1% and 83.8%, respectively, with a mean LEDD reduction of 60.6%. Improvements were comparable between G2019S carriers and non-carriers. All patients were satisfied with the treatment, though one patient had a hardware-related infection.
Conclusion: STN-DBS is effective in managing motor symptoms and reducing medication needs in EOPD patients, regardless of LRRK2-G2019S mutation status. |
|
| کلیدواژه‌های انگلیسی مقاله |
Early-onset Parkinson&apos,s disease, Deep brain stimulation, Subthalamic nucleus, LRRK2 mutations |
|
| نویسندگان مقاله |
| Hicham El Otmani
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
| Mohamed Daghi
Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Morocco
| Maha Abdallaoui
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
| Bouchra El Moutawakil
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
| Mohammed Abdoh Rafai
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
| Nadia Tahiri Jouti
Laboratory of Cellular and Molecular Inflammatory, Degenerative and Oncologic Pathophysiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Morocco
| Suzanne Lesage
Sorbonne University, Institut du Cerveau-Paris Brain Institute, ICM, INSERM, CNRS, Assistance Publique-Hôpitaux de Paris, Paris, France
| Abdelhakim Lakhdar
Neurosurgery Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
|
|
| نشانی اینترنتی |
http://bcn.iums.ac.ir/browse.php?a_code=A-10-7579-1&slc_lang=en&sid=1 |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
Clinical Neuroscience |
| نوع مقاله منتشر شده |
Original |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|